A phase I/IIa open-label study to assess the safety, tolerability and preliminary efficacy of AT7519M, a selective small molecule inhibitor of cyclin dependent kinases, in patients with refractory hematological malignancies
Phase of Trial: Phase I/II
Latest Information Update: 10 Nov 2006
At a glance
- Drugs AT 7519 (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Lymphoma; Metaplasia; Myelodysplastic syndromes; Myelofibrosis; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 10 Nov 2006 New trial record.